Results 1 to 10 of about 18,018 (235)

Understanding Consumption of Illicit Drugs and New Psychoactive Substances in Australia by Triangulating Drug Checking and Wastewater-Based Epidemiology. [PDF]

Drug Test Anal
Usman M, McLeod M, Nadarajan D, Clokey J, Prasad P, Verhagen R, Tscharke B, Quinto M, Bade R.   +8 more
europepmc   +1 more source

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.

JAMA Netw Open
Simonsson O, Bradley M, Black JC, Rockhill KM, Monte AA, Hendricks PS.   +5 more
europepmc   +1 more source

Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study. [PDF]

BMJ Open
Colcott J, Guerin AA, Carter O, Baggott MJ, Bershad A, Danforth A, de Wit H, Feduccia AA, Kirkpatrick MG, Liechti ME, Oehen P, Schmid Y, Bedi G.   +12 more
europepmc   +1 more source

Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms. [PDF]

Transl Psychiatry
Bavato F, Steuer A, Jacobsen AM, Zacher A, Zimmermann J, Cole DM, Opitz A, Baumgartner MR, Stock AK, Beste C, Quednow BB.   +10 more
europepmc   +1 more source

Group psychedelic-assisted therapy for mental health conditions: a mixed-methods systematic review. [PDF]

Front Public Health
Tsang VWL, Bhatia F, Ferrey A, Hartmann-Boyce J.   +3 more
europepmc   +1 more source

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.

Rand Health Q
Priest M, Kilmer B, Senator B, Setodji CM.   +3 more
europepmc   +1 more source

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants. [PDF]

Neuropsychopharmacology
Arikci D, Borgulya J, Straumann I, Vizeli P, Luethi D, Thomann J, Rudin D, Vukalovic I, Eckert A, Liechti ME, Holze F.   +10 more
europepmc   +1 more source